$BIOLQ
BIOLASE, INC

2024 Q3 Form 10-Q Financial Statement

#000095017024094086 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $10.85M $11.56M
YoY Change -0.65% -19.12%
Cost Of Revenue $6.468M $6.946M
YoY Change -9.85% -14.96%
Gross Profit $4.382M $4.609M
YoY Change 16.98% -24.66%
Gross Profit Margin 40.39% 39.89%
Selling, General & Admin $4.160M $6.758M
YoY Change -31.59% -20.92%
% of Gross Profit 94.93% 146.63%
Research & Development $917.0K $1.071M
YoY Change -32.67% -25.83%
% of Gross Profit 20.93% 23.24%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $5.077M $7.829M
YoY Change -31.79% -21.63%
Operating Profit -$695.0K -$3.220M
YoY Change -81.2% -16.84%
Interest Expense -$605.0K -$586.0K
YoY Change 1.17% 0.51%
% of Operating Profit
Other Income/Expense, Net -$721.0K $442.0K
YoY Change -17.79% -145.8%
Pretax Income -$1.416M -$2.778M
YoY Change -69.04% -42.57%
Income Tax $12.00K $20.00K
% Of Pretax Income
Net Earnings -$1.428M -$2.798M
YoY Change -68.88% -42.52%
Net Earnings / Revenue -13.16% -24.21%
Basic Earnings Per Share -$0.04 -$0.08
Diluted Earnings Per Share -$0.04 -$0.08
COMMON SHARES
Basic Shares Outstanding 36.60M 33.39M
Diluted Shares Outstanding 36.08M 33.39M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $3.400M $5.300M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $9.870M $10.90M
Prepaid Expenses
Receivables $3.500M $4.800M
Other Receivables
Total Short-Term Assets $19.43M $22.09M
YoY Change -30.07% -21.5%
LONG-TERM ASSETS
Property, Plant & Equipment $3.658M $4.263M
YoY Change -39.53% -33.09%
Goodwill $2.900M $2.900M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $260.0K $257.0K
YoY Change -3.7% -7.89%
Total Long-Term Assets $7.813M $8.547M
YoY Change -28.73% -25.59%
TOTAL ASSETS
Total Short-Term Assets $19.43M $22.09M
Total Long-Term Assets $7.813M $8.547M
Total Assets $27.24M $30.64M
YoY Change -29.69% -22.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.001M $5.491M
YoY Change -58.19% -13.03%
Accrued Expenses $8.153M $7.662M
YoY Change 7.09% -0.93%
Deferred Revenue $2.226M $2.132M
YoY Change 1.6% -4.65%
Short-Term Debt
YoY Change
Long-Term Debt Due $16.04M $13.28M
YoY Change 472.93%
Total Short-Term Liabilities $30.86M $31.18M
YoY Change 56.0% 69.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $150.0K
YoY Change -100.0% -98.74%
Other Long-Term Liabilities $106.0K $97.00K
YoY Change 35.9% 22.78%
Total Long-Term Liabilities $106.0K $247.0K
YoY Change -99.07% -97.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.86M $31.18M
Total Long-Term Liabilities $106.0K $247.0K
Total Liabilities $32.12M $32.77M
YoY Change -2.25% 1.47%
SHAREHOLDERS EQUITY
Retained Earnings -$327.5M -$326.1M
YoY Change 5.15% 6.26%
Common Stock $322.8M $322.4M
YoY Change 3.29% 2.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.227M -$4.329M
YoY Change
Total Liabilities & Shareholders Equity $27.24M $30.64M
YoY Change -29.69% -22.69%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$1.428M -$2.798M
YoY Change -68.88% -42.52%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of these condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and the accompanying notes. Significant estimates in these condensed consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, the provision or benefit for income taxes, and preferred stock. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, and trade accounts receivable. The Company maintains its cash and cash equivalents with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers’ financial condition and maintains relationships with the Company’s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of its products.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company’s revenue is denominated in U.S. dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company’s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the three and six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S. dollar may affect the price competitiveness of the Company’s products outside the U.S.</span></p>
CY2024Q2 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.85
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.85
CY2023Q2 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.90
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.90
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0000811240
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36385
dei Entity Registrant Name
EntityRegistrantName
BIOLASE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0442441
dei Entity Address Address Line1
EntityAddressAddressLine1
27042 Towne Centre Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
Lake Forest
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92610
dei City Area Code
CityAreaCode
949
dei Local Phone Number
LocalPhoneNumber
361-1200
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36597056
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5272000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6566000
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
329000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
244000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4842000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5483000
CY2024Q2 us-gaap Inventory Net
InventoryNet
10904000
CY2023Q4 us-gaap Inventory Net
InventoryNet
11433000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1076000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1381000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
22094000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
24863000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4263000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5525000
CY2024Q2 us-gaap Goodwill
Goodwill
2926000
CY2023Q4 us-gaap Goodwill
Goodwill
2926000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1101000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1519000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
257000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
268000
CY2024Q2 us-gaap Assets
Assets
30641000
CY2023Q4 us-gaap Assets
Assets
35101000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5491000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6065000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7662000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7518000
CY2024Q2 biol Stock Warrant Liability
StockWarrantLiability
2616000
CY2023Q4 biol Stock Warrant Liability
StockWarrantLiability
1363000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2132000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2452000
CY2024Q2 us-gaap Mediumterm Notes Current
MediumtermNotesCurrent
13275000
CY2023Q4 us-gaap Mediumterm Notes Current
MediumtermNotesCurrent
2265000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
31176000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19663000
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
186000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
256000
CY2024Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
843000
CY2023Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
593000
CY2024Q2 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
150000
CY2023Q4 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
11782000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
315000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
772000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
97000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
79000
CY2024Q2 us-gaap Liabilities
Liabilities
32767000
CY2023Q4 us-gaap Liabilities
Liabilities
33145000
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
2203000
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
2203000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33406000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33406000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3416000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3416000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
33000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
322380000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
317103000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-659000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-553000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-326083000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316800000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4329000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-247000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30641000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35101000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11555000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21687000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
6946000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
8168000
us-gaap Cost Of Revenue
CostOfRevenue
13741000
us-gaap Cost Of Revenue
CostOfRevenue
15299000
CY2024Q2 us-gaap Gross Profit
GrossProfit
4609000
CY2023Q2 us-gaap Gross Profit
GrossProfit
6118000
us-gaap Gross Profit
GrossProfit
7946000
us-gaap Gross Profit
GrossProfit
9454000
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3694000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6189000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7077000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10812000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3064000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2357000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6260000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4815000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1071000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1444000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2354000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2991000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
7829000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9990000
us-gaap Operating Expenses
OperatingExpenses
15691000
us-gaap Operating Expenses
OperatingExpenses
18618000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3220000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3872000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7745000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9164000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-112000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-235000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-208000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-215000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-586000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-583000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1208000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1160000
CY2024Q2 us-gaap Other Income
OtherIncome
1140000
CY2023Q2 us-gaap Other Income
OtherIncome
-147000
us-gaap Other Income
OtherIncome
-82000
us-gaap Other Income
OtherIncome
-147000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
442000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-965000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1498000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1522000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2778000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4837000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9243000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10686000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2798000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4868000
us-gaap Net Income Loss
NetIncomeLoss
-9283000
us-gaap Net Income Loss
NetIncomeLoss
-10717000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
39000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-106000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
119000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2818000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4829000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9389000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10598000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2798000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4868000
us-gaap Net Income Loss
NetIncomeLoss
-9283000
us-gaap Net Income Loss
NetIncomeLoss
-10717000
CY2024Q2 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
0
CY2023Q2 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
9377000
biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
0
biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
9377000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2798000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14245000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9283000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20094000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-26.14
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-26.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-45.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-45.98
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33391000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33391000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
545000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
545000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25616000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25616000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
437000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
437000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1934000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2000
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
528000
CY2024Q2 biol Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
-164000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
57000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2798000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4329000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-247000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2786000
biol Stock Issued During Period Value Class A Warrants Exercised
StockIssuedDuringPeriodValueClassAWarrantsExercised
1989000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
528000
biol Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
-164000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
159000
biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
9000
us-gaap Net Income Loss
NetIncomeLoss
-9283000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-106000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4329000
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
8158000
CY2023Q2 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
7762000
CY2023Q2 biol Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
-430000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
10980000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
404000
CY2023Q2 biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
100000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4868000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
39000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6621000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4889000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8503000
us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
7762000
biol Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
Stockissuedduringperiodpreferredstockwarrantsexercisedvalue
-430000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
10980000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
925000
biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
114000
us-gaap Net Income Loss
NetIncomeLoss
-10717000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
119000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6621000
us-gaap Profit Loss
ProfitLoss
-9283000
us-gaap Profit Loss
ProfitLoss
-10717000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1310000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1573000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
86000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
42000
biol Inventory Excess And Obsolescence
InventoryExcessAndObsolescence
76000
biol Inventory Excess And Obsolescence
InventoryExcessAndObsolescence
0
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
242000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
214000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-514000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-78000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
830000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
224000
us-gaap Share Based Compensation
ShareBasedCompensation
67000
us-gaap Share Based Compensation
ShareBasedCompensation
775000
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
232000
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-555000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-82000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-374000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
163000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-734000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-713000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-527000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1903000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-390000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
18000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6672000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9220000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
944000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
284000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
257000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-944000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2786000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8502000
biol Proceeds From The Sale Of Series H Convertible Preferred Stock Net Of Fees
ProceedsFromTheSaleOfSeriesHConvertiblePreferredStockNetOfFees
0
biol Proceeds From The Sale Of Series H Convertible Preferred Stock Net Of Fees
ProceedsFromTheSaleOfSeriesHConvertiblePreferredStockNetOfFees
2738000
biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
3020000
biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
918000
biol Principal Payment On Term Loan
PrincipalPaymentOnTermLoan
865000
biol Principal Payment On Term Loan
PrincipalPaymentOnTermLoan
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
115000
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
270000
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
520000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5219000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12793000
biol Effect Of Exchange Rate Changes
EffectOfExchangeRateChanges
-98000
biol Effect Of Exchange Rate Changes
EffectOfExchangeRateChanges
120000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1294000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2749000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6566000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4181000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5272000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6930000
us-gaap Interest Paid Net
InterestPaidNet
968000
us-gaap Interest Paid Net
InterestPaidNet
930000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
3000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
5000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
42000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
12000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
157000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
159000
biol Non Cash Property Plant And Equipment Additions Acquired Under Inventory
NonCashPropertyPlantAndEquipmentAdditionsAcquiredUnderInventory
78000
biol Non Cash Property Plant And Equipment Additions Acquired Under Inventory
NonCashPropertyPlantAndEquipmentAdditionsAcquiredUnderInventory
0
biol Common Stock Issued Upon Cashless Warrant Exercise
CommonStockIssuedUponCashlessWarrantExercise
1989000
biol Common Stock Issued Upon Cashless Warrant Exercise
CommonStockIssuedUponCashlessWarrantExercise
0
biol Common Stock Issued Upon Exercise Of Preferred Stock
CommonStockIssuedUponExerciseOfPreferredStock
528000
biol Common Stock Issued Upon Exercise Of Preferred Stock
CommonStockIssuedUponExerciseOfPreferredStock
10980000
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
0
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
483000
CY2024Q2 biol Working Capital
WorkingCapital
9100000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5300000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4800000
CY2023Q4 biol Working Capital
WorkingCapital
5200000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6600000
CY2024Q2 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.15
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.15
CY2023Q2 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.10
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.10
CY2024Q2 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
400000
CY2023Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
400000
CY2024Q2 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
407000
CY2023Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
449000
CY2024Q2 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1911000
CY2023Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
2259000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2318000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2708000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
186000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
256000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2132000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2452000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
400000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
300000
biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
900000
biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
1100000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11555000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21687000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11555000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21687000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11555000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21687000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
CY2024Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
1000000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
908
CY2024Q2 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
100000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
100000
CY2023Q2 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
100000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
800000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
100000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-46000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
84000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
775000
CY2024Q1 us-gaap Fair Value Investments Entities That Calculate Net Asset Value Per Share Percent Equity Securities
FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentEquitySecurities
0.95
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
200000
biol Offering Of Common Stock
OfferingOfCommonStock
24456808
biol Offering Of Common Stock
OfferingOfCommonStock
366154
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
5528000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
6168000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1514000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1299000
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3862000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3966000
CY2024Q2 us-gaap Inventory Net
InventoryNet
10904000
CY2023Q4 us-gaap Inventory Net
InventoryNet
11433000
CY2024Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2300000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2500000
CY2024Q2 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
16436000
CY2023Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
16695000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12328000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11330000
CY2024Q2 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
4108000
CY2023Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
5365000
CY2024Q2 us-gaap Land
Land
155000
CY2023Q4 us-gaap Land
Land
160000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4263000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5525000
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1300000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1400000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000
CY2023Q2 biol Cumulative Adjustment Depreciation Expense
CumulativeAdjustmentDepreciationExpense
800000
biol Cumulative Adjustment Depreciation Expense
CumulativeAdjustmentDepreciationExpense
800000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q2 biol Discount Rate For Fair Value Level3
DiscountRateForFairValueLevel3
0.191
CY2024Q2 us-gaap Goodwill
Goodwill
2900000
CY2023Q4 us-gaap Goodwill
Goodwill
2900000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3640000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3343000
CY2024Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1000000
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1321000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
904000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
888000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
994000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
422000
CY2024Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
349000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
452000
CY2024Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
161000
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
473000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
614000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
619000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7662000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7518000
CY2024Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1891000
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1855000
CY2023Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1914000
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1653000
CY2024Q2 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
808000
CY2023Q2 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
802000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1487000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1960000
CY2024Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
856000
CY2023Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
885000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1558000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1841000
CY2024Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1843000
CY2023Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1772000
CY2024Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1843000
CY2023Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1772000
CY2024Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
843000
CY2023Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
397000
CY2024Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
843000
CY2023Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
397000
CY2024Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1000000
CY2023Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1375000
CY2024Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1000000
CY2023Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1375000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
13425000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
14047000
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
13275000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2265000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
150000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11782000
CY2024Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
us-gaap Interest Expense Debt
InterestExpenseDebt
1200000
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
us-gaap Interest Expense Debt
InterestExpenseDebt
1200000
CY2024Q2 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.1459
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1400000
CY2024Q2 biol Long Term Debt Maturities Repayments Of Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear
896000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
12295000
CY2024Q2 biol Long Term Debt Maturities Repayments Of Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths
842000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0
CY2024Q2 biol Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
9000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3000
CY2024Q2 biol Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
6000
CY2024Q2 biol Long Term Debt Maturities Repayments Of Principal After Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
147000
CY2024Q2 biol Long Term Debt Maturities Repayments Of Interest In Year After Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFour
83000
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
13845000
CY2024Q2 biol Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
1836000
CY2024Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-12-31
CY2020Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2020Q1 biol Lease Facility Area
LeaseFacilityArea
11000
CY2020Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-07-01
CY2021Q4 biol Lease Facility Area
LeaseFacilityArea
15000
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
80000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
92000
us-gaap Operating Lease Payments
OperatingLeasePayments
157000
us-gaap Operating Lease Payments
OperatingLeasePayments
159000
CY2024Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
19000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
483000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
us-gaap Lessee Operating Lease Lease Not Yet Commenced Description
LesseeOperatingLeaseLeaseNotYetCommencedDescription
the Company had no significant leases that had not commenced.
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
919000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
410000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1330000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
111000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1219000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
904000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
315000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1219000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1100000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1200000
CY2024Q2 us-gaap Payments For Rent
PaymentsForRent
300000
us-gaap Payments For Rent
PaymentsForRent
600000
CY2023Q2 us-gaap Payments For Rent
PaymentsForRent
300000
us-gaap Payments For Rent
PaymentsForRent
600000
CY2024Q2 biol Future Minimum Payments Remainder Of Fiscal Year
FutureMinimumPaymentsRemainderOfFiscalYear
510000
CY2024Q2 biol Future Minimum Payments Due In One Year
FutureMinimumPaymentsDueInOneYear
817000
CY2024Q2 biol Future Minimum Payments Due In Two Years
FutureMinimumPaymentsDueInTwoYears
3000
CY2024Q2 biol Future Minimum Payments Due In Three Years
FutureMinimumPaymentsDueInThreeYears
0
CY2024Q2 biol Future Minimum Payments Due Thereafter
FutureMinimumPaymentsDueThereafter
0
CY2024Q2 biol Future Minimum Payments Due
FutureMinimumPaymentsDue
1330000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
111000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1219000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11555000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21687000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4263000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5525000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11555000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21687000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
CY2024Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2023Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2024Q2 biol Income Tax Provision
IncomeTaxProvision
20000
biol Income Tax Provision
IncomeTaxProvision
40000
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.007
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.004
CY2023Q2 biol Income Tax Provision
IncomeTaxProvision
31000
biol Income Tax Provision
IncomeTaxProvision
31000
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.006
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-094086-index-headers.html Edgar Link pending
0000950170-24-094086-index.html Edgar Link pending
0000950170-24-094086.txt Edgar Link pending
0000950170-24-094086-xbrl.zip Edgar Link pending
biol-20240630.htm Edgar Link pending
biol-20240630.xsd Edgar Link pending
biol-ex31_1.htm Edgar Link pending
biol-ex31_2.htm Edgar Link pending
biol-ex32_1.htm Edgar Link pending
biol-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
biol-20240630_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable